DE69624116T3 - Verfahren zur behandlung von allergischem asthma - Google Patents

Verfahren zur behandlung von allergischem asthma Download PDF

Info

Publication number
DE69624116T3
DE69624116T3 DE69624116T DE69624116T DE69624116T3 DE 69624116 T3 DE69624116 T3 DE 69624116T3 DE 69624116 T DE69624116 T DE 69624116T DE 69624116 T DE69624116 T DE 69624116T DE 69624116 T3 DE69624116 T3 DE 69624116T3
Authority
DE
Germany
Prior art keywords
ige
use according
dose
antagonist
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69624116T
Other languages
German (de)
English (en)
Other versions
DE69624116T2 (de
DE69624116D1 (de
Inventor
B. Robert FICK
M. Paula JARDIEU
B. Monika SCHOENHOFF
J. Steven SHIRE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24021032&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69624116(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of DE69624116D1 publication Critical patent/DE69624116D1/de
Publication of DE69624116T2 publication Critical patent/DE69624116T2/de
Publication of DE69624116T3 publication Critical patent/DE69624116T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69624116T 1995-07-27 1996-07-24 Verfahren zur behandlung von allergischem asthma Expired - Lifetime DE69624116T3 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50801495A 1995-07-27 1995-07-27
US508014 1995-07-27
PCT/US1996/012275 WO1997004807A1 (en) 1995-07-27 1996-07-24 Methods for treatment of allergic asthma

Publications (3)

Publication Number Publication Date
DE69624116D1 DE69624116D1 (de) 2002-11-07
DE69624116T2 DE69624116T2 (de) 2003-06-18
DE69624116T3 true DE69624116T3 (de) 2009-07-09

Family

ID=24021032

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69624116T Expired - Lifetime DE69624116T3 (de) 1995-07-27 1996-07-24 Verfahren zur behandlung von allergischem asthma

Country Status (16)

Country Link
EP (1) EP0841946B2 (https=)
JP (1) JP4153560B2 (https=)
CN (2) CN101172100A (https=)
AR (1) AR003468A1 (https=)
AT (1) ATE225185T1 (https=)
AU (1) AU715338B2 (https=)
CA (1) CA2226624C (https=)
DE (1) DE69624116T3 (https=)
DK (1) DK0841946T4 (https=)
ES (1) ES2186796T5 (https=)
IL (1) IL122733A (https=)
MX (1) MX9800760A (https=)
PT (1) PT841946E (https=)
RU (1) RU2229288C2 (https=)
WO (1) WO1997004807A1 (https=)
ZA (2) ZA966075B (https=)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6991790B1 (en) 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
WO1999045777A1 (en) * 1998-03-10 1999-09-16 The Children's Hospital Of Philadelphia Compositions and methods for treatment of asthma
US6299875B1 (en) 1998-06-04 2001-10-09 Panacea Pharmaceuticals, Llc Methods to block IGE binding to cell surface receptors of mast cells
US6913749B2 (en) 1998-11-02 2005-07-05 Resistentia Pharmaceuticals Ab Immunogenic polypeptides for inducing anti-self IgE responses
AU2002213441B2 (en) * 2000-10-12 2006-10-26 Genentech, Inc. Reduced-viscosity concentrated protein formulations
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
WO2004041863A2 (en) 2002-11-08 2004-05-21 Ablynx N.V. Single domain antibodies directed against interferon- gamma and uses therefor
EP1558645B1 (en) 2002-11-08 2011-07-27 Ablynx N.V. Stabilized single domain antibodies in pharmaceutical composition adapted for inhalation
EP1900753B1 (en) 2002-11-08 2017-08-09 Ablynx N.V. Method of administering therapeutic polypeptides, and polypeptides therefor
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
DE202006020194U1 (de) * 2006-03-01 2007-12-06 Bioceuticals Arzneimittel Ag G-CSF-Flüssigformulierung
CA2676843A1 (en) * 2007-01-29 2008-08-07 Valtion Teknillinen Tutkimuskeskus Method for producing novel ige based reagents
AR065368A1 (es) 2007-02-15 2009-06-03 Astrazeneca Ab Anticuerpos para moleculas de ige
EP2052736A1 (en) * 2007-10-26 2009-04-29 Nycomed Danmark ApS Parathyroid hormone formulations und uses thereof
BRPI0821591A2 (pt) * 2007-12-21 2016-05-03 Inspiration Biopharmaceuticals Inc composição liofilizada e métodos de preparação de composição seca estável do fator ix e de liofilização de formulação farmacêutica
BRPI0820819B1 (pt) * 2007-12-21 2021-06-08 F. Hoffmann-La Roche Ag formulação de anticorpos humanizados b-ly 1 e seu uso
MX344559B (es) 2008-04-29 2016-12-20 Ascendis Pharma As Compuestos de hormona de crecimiento humana recombinante unidos al peg.
CA2738243C (en) * 2008-10-29 2020-09-29 Wyeth Llc Formulations of single domain antigen binding molecules
BRPI0919879A2 (pt) 2008-10-29 2016-02-16 Wyeth Llc métodos para purificação de moléculas de ligação a antígeno de domínio único
MX337432B (es) 2009-12-15 2016-03-04 Ascendis Pharma As Composicion de la hormona del crecimiento seca enlazada transitoriamente a un portador del polimero.
ES2993140T3 (en) 2010-04-02 2024-12-23 Amunix Pharmaceuticals Inc Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
CN102533704A (zh) * 2010-12-30 2012-07-04 上海雅心生物技术有限公司 即配即用型的胰蛋白酶制剂
PT2691112T (pt) * 2011-03-31 2018-07-10 Merck Sharp & Dohme Formulações estáveis de anticorpos para o recetor pd-1 humano de morte programada e tratamentos relacionados
CN107233569B (zh) * 2011-10-25 2021-08-31 普罗西纳生物科学有限公司 抗体制剂和方法
EP3689335A1 (en) 2013-09-27 2020-08-05 Hanmi Pharm. Co., Ltd. Sustained type human growth hormone preparation
CN104707146B (zh) * 2013-12-16 2019-04-16 浙江海正药业股份有限公司 一种含有阿达木单抗的药物组合物
SG11201703870UA (en) 2014-11-18 2017-06-29 Ascendis Pharma Endocrinology Div As Novel polymeric hgh prodrugs
PT3220892T (pt) 2014-11-21 2021-11-05 Ascendis Pharma Endocrinology Div A/S Formas de dosagem de hormona do crescimento de longa ação
GB201610198D0 (en) 2016-06-10 2016-07-27 Ucb Biopharma Sprl Anti-ige antibodies
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
JP7382232B2 (ja) 2017-05-02 2023-11-16 メルク・シャープ・アンド・ドーム・エルエルシー 抗ｌａｇ３抗体の製剤および抗ｌａｇ３抗体と抗ｐｄ－１抗体との共製剤
WO2019019998A1 (zh) * 2017-07-25 2019-01-31 江苏恒瑞医药股份有限公司 一种il-15蛋白复合物药物组合物及其用途
KR20220098056A (ko) * 2018-02-09 2022-07-08 제넨테크, 인크. 비만 세포 매개 염증성 질환에 대한 치료 및 진단 방법
CN110732023B (zh) * 2018-07-18 2023-06-16 江苏恒瑞医药股份有限公司 一种her2抗体药物组合物及其用途
MX2021004928A (es) 2018-10-31 2021-06-08 Merck Sharp & Dohme Llc Cristales de anticuerpo anti-pd-1 humano y metodos de uso de los mismos.
AU2020233198B2 (en) 2019-03-04 2025-05-15 Ascendis Pharma Endocrinology Division A/S Long-acting growth hormone dosage forms with superior efficacy to daily somatropin
CN113827717A (zh) * 2020-06-23 2021-12-24 三生国健药业（上海）股份有限公司 抗her2单克隆抗体冻干制剂及制备方法
CA3185192A1 (en) 2020-07-10 2022-01-13 Sujun DENG Anti-ige engineered antibody and application thereof
TW202409078A (zh) * 2022-07-18 2024-03-01 中國大陸商蘇州創勝醫藥集團有限公司 穩定之包含抗gremlin1抗體的藥物製劑

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3729863A1 (de) * 1987-09-05 1989-03-16 Boehringer Mannheim Gmbh Stabilisierte erythropoietin-lyophilisate
AU616916B2 (en) * 1987-11-20 1991-11-14 Kissei Pharmaceutical Co. Ltd. 4h-quinolizin-4-one compounds exhibiting therapeutic activities
AU618317B2 (en) * 1987-12-31 1991-12-19 Tanox Biosystems, Inc. Unique antigenic epitopes on ige-bearing b lymphocytes
US5011676A (en) * 1990-03-27 1991-04-30 Thomas Jefferson University Method to directly radiolabel antibodies for diagnostic imaging and therapy
US5290764A (en) * 1992-01-14 1994-03-01 The Dupont Merck Pharmaceutical Company Stabilization of active plasminogen activator inhibitor-1
EP0651819A1 (en) * 1992-03-20 1995-05-10 Immunet Methods for human monoclonal antibody production
JPH07118168A (ja) * 1993-10-19 1995-05-09 Tomoyasu Ra ＩｇＥ産生抑制剤
ES2219640T3 (es) * 1992-09-24 2004-12-01 Novartis Ag Anticuerpos monoclonales reformados contra un isotopo de inmunoglobulina.
DE4344824C1 (de) * 1993-12-28 1995-08-31 Immuno Ag Hochkonzentriertes Immunglobulin-Präparat und Verfahren zu seiner Herstellung
FR2719479B1 (fr) * 1994-05-04 1996-07-26 Sanofi Elf Formulation stable lyophilisée comprenant une protéine: kit de dosage.

Also Published As

Publication number Publication date
AU6638196A (en) 1997-02-26
EP0841946B1 (en) 2002-10-02
DE69624116T2 (de) 2003-06-18
CN101172099B (zh) 2012-02-15
JP4153560B2 (ja) 2008-09-24
AU715338B2 (en) 2000-01-20
CN101172099A (zh) 2008-05-07
ES2186796T3 (es) 2003-05-16
ES2186796T5 (es) 2009-04-01
IL122733A0 (en) 1998-08-16
CA2226624A1 (en) 1997-02-13
DE69624116D1 (de) 2002-11-07
IL122733A (en) 2001-09-13
EP0841946A1 (en) 1998-05-20
EP0841946B2 (en) 2008-10-15
DK0841946T3 (da) 2003-02-10
DK0841946T4 (da) 2009-02-16
AR003468A1 (es) 1998-08-05
MX9800760A (es) 1998-04-30
RU2229288C2 (ru) 2004-05-27
ZA966075B (en) 1998-01-19
CA2226624C (en) 2013-07-16
PT841946E (pt) 2003-02-28
JPH11510172A (ja) 1999-09-07
CN101172100A (zh) 2008-05-07
WO1997004807A1 (en) 1997-02-13
ZA966240B (en) 1998-01-23
ATE225185T1 (de) 2002-10-15

Similar Documents

Publication Publication Date Title
DE69624116T3 (de) Verfahren zur behandlung von allergischem asthma
DE69501817T2 (de) Verfahren zur behandlung von parasitären infektionen unter verwendung von ige-antagonisten
US20090087426A1 (en) Methods for Treatment of Allergic Asthma
DE69534075T2 (de) Vorbeugungs- und heilmittel für erkrankungen, die durch fibrin- oder thrombusbildung hervorgerufen werden
MXPA98000760A (en) Methods for the treatment of asthma allergy
DE69033461T2 (de) Auf membran-gebundenem, nicht aber auf sezerniertem iga vorkommende antigene epitope
DE3853636T3 (de) Antigene epitope, die sich ausschliesslich auf ige-tragenden b-lymphocyten befinden.
US20200040073A1 (en) Methods for administering anti-il-5 antibodies
DE69620174T2 (de) Behandlung von t-zellmediierten autoimmunkrankheiten
DE69126607T2 (de) Extrazelluläre teilstücke humaner ige-immunoglobulin-ankerpeptide und dafür spezifische antikörper
DE60127237T2 (de) Therapeutischer monoklonaler rekombinanter anti-ige antikörper gegen hunde-allergie
DE69626423T2 (de) Verfahren und zusammensetzung zum rekonformieren multiepitopischer antigene zum anregen einer immunantwort
DE112011102640T5 (de) Pharmazeutische Kombinationszusammensetzung und Verfahren zur Behandlung undPrävention von Infektionskrankheiten
DE69825473T2 (de) Cd154-blockadetherapie für das syndrom der hemmung der therapeutischen proteine
DE68908431T2 (de) Methode zur Verminderung der Immunglobulin-E-Reaktion.
EP1230932A2 (de) Verwendung von Antikörpern zur Vakzinierung gegen Krebs
DE202021004005U1 (de) Ofatumumab zur Behandlung von MS unter Beibehaltung des IgG im Serum
DE69813070T2 (de) Pharmazeutische Zubereitung zur oralen Anwendung enthaltend einen Histamin-Immunoglobulin Komplex
DE3854926T2 (de) Verwendung von antikörper gegen angiogenin: immunotherapeutische mittel
DE2710455C2 (de) N-Acetylmuramyl-L-alanyl-D-glutaminsäure-alpha-methylamid, Verfahren zu seiner Herstellung und diese Verbindung enthaltende Arzneimittel
DE69215568T2 (de) Verfahren zur Hemmung der Sauerstofftoxizität in den Lungen
DE69937057T2 (de) Verwendung von basiliximab zur behandlung von rheumatoider arthritis und hauterkrankungen
WO1997010004A1 (en) Methods for treatment of interstitial cystitis

Legal Events

Date Code Title Description
8363 Opposition against the patent
8366 Restricted maintained after opposition proceedings